Custom Host Cell Line Development

Today, more than 60% of recombinant proteins used for therapeutic applications are produced in mammalian cells. Although mammalian production systems are still costly and time consuming, when compared to bacterial or yeast expression systems, they offer unique advantages such as appropriate protein folding, assembly and posttranslational modification, factors that are major determinants for the biological activity and product quality. Although most biotherapeutic proteins developed to date have been produced using mammalian Chinese hamster ovary and murine myeloma (NS0, Sp2/0) cell lines, there has been a recent shift toward the use of human cell lines. One of the most important advantages of using human cell lines for protein production is the greater likelihood that the resulting recombinant protein will bear post-translational modifications that are consistent with those seen on endogenous human proteins. Another advantage is that human cell lines are grown easily in a serum-free suspension culture, reproduce rapidly and have efficient protein production.

Production of biotherapeutic proteins in human cell lines is expanding, with several products currently approved for clinical use and other in clinical development in different therapeutic areas. Human cell lines will be further optimized, more sophisticated product collection strategies will be developed, and these cell lines may become one of the preferred platforms for protein biotherapeutic production.

Creative Bioarray has developed human highly immortalized differentiated cell lines from various human tissues that show stable growth characteristics and phenotypes and have a high potential for production of complex biopharmaceuticals such as recombinant proteins, vaccines or extracellular vesicles. Creative Bioarray provides already established cell lines to get proof-of-principle for new production hosts, establishes customer-tailored cell lines as novel production hosts.